QUECTEL-WIRELESS
14.3.2023 09:02:03 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces how its latest smart module with machine compute and edge intelligence capabilities is revolutionizing the color sorter industry with higher efficiency and accuracy. Employing Quectel’s high performance SG560D smart module, the solution improves the color sorting of industrial materials that can be transformed via a visual identification system, through a combination of machine vision and edge intelligence capabilities, and automatically sort objects based on color and shapes accordingly.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005130/en/
Quectel showcases industrial smart color sorter solution with edge intelligence at Embedded World 2023
The advanced color sorter application, aimed at the industrial materials management industry, utilizes the Quectel SG560D smart module based on the Qualcomm QCS6490 chipset, and additional integrated hardware including cameras, lamps, and air guns. The solution is able to detect, recognize, and sort a broad array of textures, colors and materials including food materials such as rice, wheat, corn, soybean, seeds, nuts, salt, plastic objects such as plastic pieces, plastic granules, plastic bottle cap flake as well as minerals like quartz stone, quartz sand, pearls, marble, and others.
“As a global leader, Quectel is committed to serving our customers across all industries with the latest innovative technologies. We are proud to drive innovations in large industrial verticals such as color sorting where machine vision, edge computing and next-generation robotics applications can transform entire industries with faster time-to-market, increase productivity and produce significant cost-savings,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions.
With advanced visual identification system, the smart color sorter solution can manage color sorting of high-volume objects with four cameras working simultaneously to stream video, with an accuracy of less than 1/200000 error rate. Additionally, it can help reduce operating and labor expense significantly.
Quectel’s SG560D is a powerful smart module equipped with a Qualcomm® Kryo™ 670 CPU built on Arm v8 Cortex technology and a Qualcomm® Adreno™ 642L GPU. It also features 2 x HVX high-performance digital signal processing (DSP), which bring superior computing power to enable fast, high-quality data processing and make quicker, data-driven decisions. Tests indicate that the SG560D module can achieve computing performance of up to 14 trillion operations per second (TOPS).
The SG560D also supports 5G new radio (NR), Wi-Fi 6E bands of 2.4 GHz, 5 GHz and 6 GHz, dual-band simultaneous (DBS), Wi-Fi 2x2 MU-MIMO and Bluetooth 5.2, which significantly improves network coverage and enhances transmission data rates in different application scenarios.
To learn more, visit the Quectel booth at Embedded World 2023, Hall 3, Booth 318 where we will be demonstrating Quectel’s smart module solutions with machine vision and edge capabilities.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services.
Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005130/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom